¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reactive hemolysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reactive angioendotheliomatosis
    ¹ÝÀÀÇ÷°ü³»ÇÇÁ¾Áõ
  • reactive arthritis
    ¹ÝÀÀ°üÀý¿°
  • reactive attachment disorder
    ¹ÝÀÀ¼º¾ÖÂøÀå¾Ö
  • reactive bone excrescence
    ¹ÝÀÀ»Àµ¹Ãâ
  • reactive depression
    ¹ÝÀÀ¿ì¿ïÁõ
  • reactive fibrosis
    ¹ÝÀÀ¼¶À¯È­
  • reactive hyperemia
    ¹ÝÀÀÃæÇ÷
  • reactive hypoglycemia
    ¹ÝÀÀÀúÇ÷´ç(Áõ)
  • reactive inflammation
    ¹ÝÀÀ¿°Áõ
  • reactive interface
    ¹ÝÀÀÁ¢Ã˸é
  • reactive intermediate
    ¹ÝÀÀÁß°£¹°Áú
  • reactive nodular hyperplasia
    ¹ÝÀÀ¼º°áÀýÁõ½Ä
  • venom hemolysis
    ¹ìµ¶¿ëÇ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gamma hemolysis
    °¨¸¶¿ëÇ÷
  • hemolysis
    ¿ëÇ÷
  • hot-cold hemolysis
    ¿Â³Ã󸮿ëÇ÷
  • immune hemolysis
    ¸é¿ª¿ëÇ÷
  • immune-mediated hemolysis
    ¸é¿ª¸Å°³¿ëÇ÷
  • intravascular hemolysis
    Ç÷°ü³»¿ëÇ÷
  • osmotic hemolysis
    »ïÅõ¿ëÇ÷
  • reactive hyperemia
    ¹ÝÀÀÃæÇ÷
  • reactive hypoglycemia
    ¹ÝÀÀÀúÇ÷´çÁõ
  • reactive nodular hyperplasia
    ¹ÝÀÀ°áÀýÁõ½Ä
  • siderogenous hemolysis
    ö¹ß»ý¿ëÇ÷
  • venom hemolysis
    ¹ìµ¶¿ëÇ÷
  • reactive inflammation
    ¹ÝÀÀ¿°Áõ
  • reactive interface
    ¹ÝÀÀÁ¢Ã˸é
  • reactive intermediate
    ¹ÝÀÀÁß°£¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired reactive perforating dermatosis
    ÈÄõ¼º ¹ÝÀÀ¼º õ°ø¼º ÇǺκ´
  • acute phase reactive protein
    ±Þ¼º±â ¹ÝÀÀ¼º ´Ü¹é.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • reactive angioendotheliomatosis
    ¹ÝÀÀ¼º Ç÷°ü ³»ÇÇÁ¾Áõ
  • reactive arthritis
    ¹ÝÀÀ¼º°üÀý¿°
  • reactive attachment disorder
    ¹ÝÀÀ¼º ¾ÖÂø(äñó·)Àå¾Ö(º´)
  • reactive bone excrescence
    ¹ÝÀÀ¼º °ñ µ¹Ãâ
  • reactive depression
    ¹ÝÀÀ¼º ¿ì¿ïÁõ(ÚãëëàõéØê¦ñø).
  • reactive eosinophilia
    ¹ÝÀÀ¼º È£»ê±¸Áõ´ÙÁõ
  • reactive epilepsy
    ¹ÝÀÀ¼º °£Áú(¡­ÊÖòð).
  • reactive epilepsy
    ¹ÝÀÀ¼º °£Áú(ÚãëëàõÊÖòð)
  • reactive fibrosis
    ¹ÝÀÀ¼º ¼¶À¯È­
  • reactive functional hypoglycemia
    ¹ÝÀÀ¼º ±â´É¼º ÀúÇ÷´ç(¡­Ñ¦Òöàõî¸úìÓØ).
  • reactive hyperemia
    ¹ÝÀÀ¼º ÃæÇ÷(¡­õöúì)
  • reactive hypoglycemia
    ¹ÝÀÀ¼º ÀúÇ÷´çÁõ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemolysis
    ¿ëÇ÷(éÁúì).
  • hemolysis
    ¿ëÇ÷(éÁúì)
  • hemolysis, hot-cold
    ¿Â³Ã󸮿ëÇ÷
  • hemolysis, immune
    ¸é¿ª¿ëÇ÷
  • immune hemolysis
    ¸é¿ª¿ëÇ÷(¹ÝÀÀ).
  • immune-mediated hemolysis
    ¸é¿ª¸Å°³¼º ¿ëÇ÷
  • intravascular hemolysis
    Ç÷°ü³»¿ëÇ÷
  • nonimmune hemolysis
    ºñ¸é¿ª¼º¿ëÇ÷
  • osmotic hemolysis
    »ïÅõÀû ¿ëÇ÷(ß¶÷âîÜéÁúì).
  • osmotic hemolysis
    »ïÅõÀû ¿ëÇ÷(Ë×Ì¬ËøËíÌ´).
  • siderogenous hemolysis
    ö¹ß»ý¼º ¿ëÇ÷(ôÑÛ¡ßæàõéÁúì).
  • siderogenous hemolysis
    ö¹ß»ý¼º ¿ëÇ÷(ôÑÛ¡ßæàõéÁúì)
  • sucrose hemolysis test
    ÀÚ´ç¿ëÇ÷½ÃÇè
  • sucrose hemolysis test
    ÀÚ´ç¿ëÇ÷°Ë»ç
  • venom hemolysis
    »çµ¶¿ëÇ÷(ÞïÔ¸éÁúì).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
KHC kinetic hemolysis curve
LHG left hand grip; localized hemolysis in gel
RCPH red cell peroxide hemolysis
SRH single radial hemolysis; somatotropin-releasing hormone; spontaneously responding hyperthyroidism; s...
CREG Cross REactive Group (of HLA Antigens)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TBARS 2-Thiobarbituric acid-reactive substances
TBARS 2-thiobarbituric reactive substances
CRP C - reactive protein
CRI Cross-reactive idiotypes
IRI Immuno Reactive Insulin
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
C-reactive protein <protein> This blood test is used as an indicator of acute inflammation. C-reactive protein is a protein of the pentraxin family, produced by the liver during periods of inflammation and detectable in serum in various disease conditions particularly during the acute phase of immune response. Normally C-reactive protein should be negative in the bloodstream.
C-reactive protein is synthesised by hepatocytes and its production may be triggered by prostaglandin E1 or parogen. It consists of five polypeptide sub units forming a molecule of total molecular weight 105 kD. It binds to polysaccharides present in a wide range of bacterial, fungal and other cell walls or cell surfaces and to lecithin and to phosphoryl or choline containing molecules. It is related in structure to Serum Amyloid. And C polysaccharide.
Conditions which can cause a positive C-reactive protein include: rheumatoid arthritis, lupus, pneumococcal pneumonia, rheumatic fever, cancer, tuberculosis and myocardial infarction.
A positive C-reactive protein may also be seen in the later half of pregnancy and in some who are taking birth control pills.
See: acute phase proteins
(06 Oct 1997)
cross-reactive antibody <haematology, immunology> Antibodies which don't respond to any one specific antigen, but will respond to a number of them. These antibodies can be responsible for false positive results in antigen-antibody tests.
(09 Oct 1997)
thiobarbituric acid reactive substances Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á